We discovered that APOE4 increases α-Syn pathology via cholesterol dysregulation, suggesting that the APOE genotype may impact whether cholesterol-lowering medications can benefit classic synucleinopathies and co-pathological presentations of pathogenic α-Syn such as AD with Lewy Bodies. The gene discussed is APOE; the disease is synucleinopathy.